The Top Ten Biotech Stocks Right Now

Why it leads this edition: Agios is the entry that comes closest to what this ranking rewards. It has an exact FDA date, a product already selling in two approved indications, a balance sheet that does not depend on the decision, and a downside that removes an expansion rather than the company. The FDA accepted the supplemental New Drug Application for mitapivat in sickle cell disease with Priority Review and set a goal date of November 1, 2026, under the accelerated approval pathway.

Mitapivat is an oral pyruvate kinase activator sold as PYRUKYND in pyruvate kinase deficiency and as AQVESME in thalassemia. Sickle cell disease is by a wide margin the largest population the molecule has been taken into, which is why the November decision matters more to the revenue line than either existing indication did. In the second quarter of 2026 worldwide mitapivat net revenue reached $44.7 million, against $12.5 million in the same quarter of 2025, and the company reported 442 cumulative AQVESME prescriptions written in the U.S. thalassemia launch as of June 30, 2026.

What matters now: the specific question in front of the agency is whether a haemoglobin response of at least 1.0 g/dL, sustained from Week 24 through Week 52, is an acceptable surrogate in a disease whose clinical burden is measured in pain crises. That is the argument the review has to settle, and it is the same argument that will define the label if the answer is yes. The confirmatory trial design feedback and the breadth of any approved population are the two details worth reading first on November 1.

Merlintrader view: $AGIO offers the ranking’s best combination of a dated decision and a company that survives either answer. The counterweight is that the evidence package is genuinely split, and a reader who only sees “met its primary endpoint” has read half of the trial.

Why it ranks second: one of Ultragenyx’s three near-term events resolved positively, one is still open and the third has failed. On August 19, 2026, the FDA granted accelerated approval to GENGLYCOS, formerly DTX401, for adults and pediatric patients aged eight years and older with glycogen storage disease type Ia. On September 2, 2026 the Phase 3 Aspire study of apazunersen (GTX-102) in Angelman syndrome missed both its primary and its key secondary endpoint. What remains inside this window is one commercial launch and one open PDUFA on September 19, which is a narrower setup than the one that held first place in the previous edition.

What Aspire reported. The 129-patient pivotal study did not achieve the primary endpoint, change from baseline in the Bayley-4 cognitive raw score, nor the key secondary endpoint, net response in the Multidomain Responder Index. Ultragenyx states that the randomized groups were comparable at baseline and consistent with the patients studied in Phase 2, and that there were no differences between the treated and control groups either in the Bayley cognition raw scores or in the MDRI, whether measured as net response or as the mean changes of the five individual endpoints inside it. The safety profile was consistent with Phase 1/2. The company says it will evaluate the apazunersen programme and decide its disposition, and that it will assess planned operations to define and implement significant expense reductions while supporting the commercial business.

GENGLYCOS (pariglasgene brecaparvovec-opnr) is the first approved treatment for GSDIa. Its indication is to reduce daily cornstarch intake as an adjunct to nutritional management. The accelerated approval is based on reduced cornstarch intake, and continued approval may depend on verification of clinical benefit through confirmatory evidence. Ultragenyx also received a Rare Pediatric Disease Priority Review Voucher. For UX111, the FDA accepted the resubmission and assigned a September 19 action date.

What matters now: three things. The September 19 UX111 decision in Sanfilippo syndrome type A, which is the only dated regulatory event Ultragenyx has left inside this window. The GENGLYCOS launch, where attention shifts from the FDA decision to activation of qualified treatment centers, insurance coverage, adoption and execution of post-marketing commitments. And the two things the September 2 release announced without quantifying: what happens to apazunersen, and how large the expense reductions turn out to be.

Merlintrader view: the entry stays high in the ranking because the commercial platform, the approved GENGLYCOS and the September 19 decision all survive September 2 intact. It stops being first because the ranking rewards catalyst density, and that density has halved: one pivotal readout has failed, one launch has to be executed and one decision remains. Launch risk, confirmatory obligations and the unquantified expense reductions are the three items that now define the rest of the year.

The central catalyst: Pharvaris expects topline results from CHAPTER-3 during the third quarter of 2026. The pivotal study evaluates once-daily extended-release deucrictibant for prophylactic treatment of hereditary angioedema. Approximately 81 participants were randomized 2:1 to active treatment or placebo for 24 weeks.

This is one of the cleaner clinical setups on the list because the molecule is not entering the pivotal stage without supporting evidence. Deucrictibant has generated data in both acute and prophylactic settings, and the same oral bradykinin B2 receptor antagonism underpins the broader program. The immediate-release formulation also reached a major regulatory milestone when its U.S. NDA was accepted in July 2026, although its PDUFA date falls in April 2027 and therefore sits outside the current ranking’s active review window.

The data details that matter: annualized attack rate, proportion of attack-free patients, consistency across subgroups, rescue-medication use, treatment discontinuations and any signal that efficacy weakens over time. A headline beat is important, but competitive positioning will depend on the entire profile.

Merlintrader view: $PHVS is the best pure pivotal-readout setup in the ranking. It still carries normal Phase 3 risk, but the combination of prior validation, a defined market and adequate capital gives the event a more balanced structure than many binary biotech readouts.

The story in short: Disc Medicine develops treatments for serious blood disorders. Its lead candidate, bitopertin, is an oral GlyT1 inhibitor for erythropoietic protoporphyria, a rare inherited condition in which a build-up of protoporphyrin IX makes sunlight exposure painful. The company filed for accelerated approval using the reduction of that molecule as a surrogate endpoint, and on February 13, 2026 the FDA issued a Complete Response Letter. The agency accepted that bitopertin lowers PPIX significantly; what it did not accept was the link between that reduction and the endpoints measuring actual time in sunlight. The drug worked on the biomarker, and the biomarker was not enough.

Why it is here now: the company did not have to start over. After a Type A meeting, Disc and the FDA agreed that the Phase 3 APOLLO study, if successful, can serve as the basis for the CRL response and could support a traditional approval rather than an accelerated one. APOLLO finished enrolling in March 2026 ahead of schedule, with a final size of 183 participants after being expanded on patient and physician demand, and topline data are guided to the fourth quarter of 2026. Management expects to submit the CRL response and receive an FDA decision by mid-2027. A separate Expanded Access Program launched in June already provides the drug to eligible patients ahead of any decision.

Merlintrader view: $IRON remains No. 4 because APOLLO is still the decisive asset-level event and the FDA-agreed recovery path is unchanged. The SOHO presentations add two nearer clinical checkpoints and reduce the risk that the rest of the pipeline is treated as a black box, but they do not move the APOLLO timeline or substitute for a registrational result. The honest caveat remains timing: the lead readout is guided to the fourth quarter, beyond the November 1 edge of this review window.

Telix’s September 11 catalyst concerns Pixclara, a PET imaging agent intended to help evaluate recurrent or progressive glioma and distinguish active disease from treatment-related changes. The FDA accepted the NDA and granted a review path supported by Orphan Drug and Fast Track designations.

The medical need is clear: post-treatment brain imaging can be difficult to interpret, and clinicians may struggle to separate true tumor progression from pseudoprogression or radiation-related changes. A more informative imaging tool could improve treatment decisions, patient selection and clinical-trial assessment.

What matters after approval: final label breadth, reimbursement, U.S. launch timing, production capacity, distribution reliability and evidence that Pixclara changes clinical decision-making. Radiopharmaceutical products require more operational infrastructure than conventional tablets, and execution remains critical even after regulatory success.

Merlintrader view: $TLX is included because it offers a cleaner corporate-risk profile than most catalyst trades. The likely percentage reaction may be smaller, but the event sits inside a durable radiopharma growth platform rather than a single-asset survival story.

GRAIL enters the ranking because 23 September is the rarest kind of catalyst on this list: a public advisory committee vote on the one product the company is built around. The FDA’s Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee will review the premarket approval application for Galleri, a blood test that looks for cancer-specific methylation patterns in cell-free DNA and, when it finds a signal, predicts where in the body the cancer originated. The application was submitted on 29 January 2026 and the public docket, FDA-2026-N-8004, closes on 16 September.

Why the setup can work

• The evidence base is unusually large for a diagnostic. The submission rests on 25,490 consented participants with one year of follow-up in the U.S. PATHFINDER 2 study, plus more than 70,000 participants from the intervention arm of the prevalent screening round of NHS-Galleri, which remains the only randomised controlled trial of a multi-cancer test in an intended-use population.
• In PATHFINDER 2, adding Galleri to recommended screening allowed roughly 60% of cancers to be identified by screening, a 6.5-fold increase over the cancers found by the USPSTF A and B screens alone. The test identified the cancer signal origin correctly more than 90% of the time.
• The commercial base already exists rather than being a projection. Galleri revenue rose 24% year over year to $42.6 million in the second quarter on more than 61,000 tests, and first-half revenue rose 30% to $82.5 million on more than 117,000 tests.
• The balance sheet can absorb a delay. Cash, cash equivalents and short-term marketable securities stood at $861.6 million at 30 June 2026, after a $110 million equity investment from Samsung C&T and Samsung Electronics completed in June alongside a South Korea commercialisation agreement.

What can break the thesis

• The NHS-Galleri result is not clean, and GRAIL says so itself. In the company’s own words the test did not produce a significant decrease in combined Stage III and IV cancers. What it did show was a 22% and 26% reduction in Stage IV diagnoses of twelve prespecified aggressive cancers in the second and third screening rounds. A panel that focuses on the prespecified combined endpoint rather than the aggressive-cancer subset will be looking at a miss.
• An advisory committee is a vote, held in public, by people who do not work for the company. It is not binding on the FDA, but a negative vote is difficult to unwind and the discussion itself sets the terms of the reimbursement debate that follows.
• Screening tests carry a burden that therapeutics do not: false positives lead to diagnostic workups in healthy people, and the panel will weigh that harm explicitly.
• The company is still deeply loss-making. Net loss was $110.2 million in the second quarter and adjusted EBITDA was negative $90.3 million, so the cash pile buys time rather than independence.

Why this is a single-asset risk

Unlike most names on this list, GRAIL does not have a second programme that carries the company if the first one stalls. Galleri is the revenue, the pipeline and the story. That concentration is what makes 23 September a genuine binary rather than one input among several, and it is also the reason the entry does not sit higher: the evidence is strong on detection and ambiguous on the endpoint that regulators asked for.

Mirum takes the seventh slot on a dated FDA decision that arrives into a market which changed on August 19, 2026. Zilurgisertib is an oral inhibitor of activin receptor-like kinase 2, the receptor that is abnormally active in most people with fibrodysplasia ossificans progressiva and drives bone formation in soft tissue. The FDA accepted the application under Priority Review with a target action date of 26 September 2026. Mirum licensed the compound from Incyte for worldwide development and commercialisation, so the approval economics sit with Mirum rather than with the originator.

Why the setup can work

• The supportive endpoints are unusually clean for an ultra-rare disease. In Cohort 1 of the PROGRESS study, 63 patients aged twelve and over were randomised one to one to zilurgisertib 100 mg once daily or placebo for 24 weeks. New heterotopic ossification lesion volume was more than 99% lower on drug (nominal p<0.0001), and total lesion volume fell by 3.24 cm³ on treatment against a 24.64 cm³ increase on placebo (nominal p=0.004).
• The open-label extension held up. Through Week 48 no new lesions were observed either in patients who stayed on drug or in those who crossed over from placebo, and total lesion volume kept falling.
• Tolerability was undramatic: adverse events mostly mild or moderate, and no adverse event led to discontinuation or dose reduction.
• Mirum is not a single-asset company waiting on this decision. Second-quarter net product sales were $176 million from LIVMARLI, CHOLBAM and CTEXLI, and full-year guidance was raised to $680–700 million. The pipeline also holds volixibat in primary sclerosing cholangitis and primary biliary cholangitis, brelovitug in hepatitis delta and MRM-3379 in Fragile X.

What can break the thesis

• The primary endpoint did not reach conventional statistical significance. The proportion of patients developing new heterotopic ossification lesions at Week 24 was 3.1% on zilurgisertib against 16.7% on placebo — an 81% relative reduction, but with p=0.0986. The impressive volume and flare numbers are labelled nominal p-values by the company itself. A reviewer who anchors on the prespecified primary is looking at a study that missed.
• The market is now contested. On 19 August 2026 the FDA approved Regeneron’s Pasatru in the same disease, which the agency described as the second approved treatment for it. Zilurgisertib would arrive into a population the FDA and Mirum both put at roughly 300 patients in the United States and 900 worldwide, with a competitor already launched.
• Cohort 1 covered patients aged twelve and over. The younger cohorts, ages six to under twelve and two to under twelve, are still running, so the label at first approval would not cover the full paediatric population.
• Because the asset is licensed, part of the economics is shared with Incyte, and the approval is worth less to Mirum than a wholly owned product of the same size would be.

Why it sits in the middle rather than higher

The catalyst is dated, near and genuinely binary at the label level, which is what earns the slot. What keeps it out of the top five is that a positive decision adds a small rare-disease launch to a company already guiding to nearly $700 million of sales, while a negative one removes an option rather than the business. That is a narrower outcome range than the names above it, and the ranking reflects that rather than any doubt about the science.

Why it enters at No. 8: the catalyst is an exact FDA date on a product that is already approved, already reimbursed and already generating revenue in a different indication. The FDA accepted the supplemental New Drug Application for Ameluz photodynamic therapy in superficial basal cell carcinoma with no filing deficiencies and set a target action date of September 28, 2026. What holds the entry down the list is not the science, it is the balance sheet: Biofrontera ended the second quarter with $4.7 million of cash.

Ameluz, a nanoemulsion of aminolevulinic acid used with the RhodoLED red-light lamp series, is approved in the United States for actinic keratosis. An sBCC label would be the first time a photodynamic therapy is approved in the country for a cancerous tumour rather than a precancerous lesion, and basal cell carcinoma is the most common cancer in the United States, with roughly 3.6 million cases a year, of which published estimates place 10% to 25% in the superficial subtype. The company has said a full launch would follow in the first quarter of 2027.

What matters now: two things decide this one. The first is the September 28 action itself. The second, which is easy to overlook, is how Biofrontera funds a launch from a $4.7 million starting position, whether through operating cash flow, the convertible structure or a raise on whatever terms the decision produces.

Merlintrader view: $BFRI is the clearest example on this list of a company whose catalyst quality and financial resilience point in opposite directions. The clinical evidence behind the filing is the strongest argument for the entry; the cash line is the reason it does not rank higher.

The immediate setup: SELLAS said on August 11 that REGAL was approaching the prespecified 80th event and repeated that it will announce when the trigger occurs. The last numerical disclosure remains 78 of 80 events as of May 11; no official announcement identified through September 3 confirms that the 80th event has occurred. The trigger will start database lock, blinded review, statistical analysis, unblinding and the later disclosure of topline overall-survival results.

That keeps GPS as the closest binary, but the Q2 update also makes the second program more investable as a separate thesis. SLS009, or tambiciclib, is now dosing in an 80-patient Phase 2 study in newly diagnosed frontline AML, including patients identified as becoming refractory early to azacitidine/venetoclax.

Merlintrader view: $SLS moves to No. 9, below every dated decision on the list for one reason only: after fifteen months the 80th event still has no date. REGAL is still the dominant near-term binary, but the Q2 cash build and a measurable SLS009 enrollment/data timeline make the second asset materially more relevant than it was in the previous version. Neither the prolonged REGAL clock nor the PDAC experiments should be presented as clinical efficacy proof.

Why it enters at No. 10: the date is exact and the outcome is genuinely binary, but almost everything around it is fragile. The FDA is reviewing the Biologics License Application for INO-3107 in recurrent respiratory papillomatosis with a target action date of October 30, 2026. The late-cycle review meeting and all scheduled pre-licensure inspections are complete. What keeps the entry at the bottom of the ranking is that INOVIO has never had an approved product, funds itself quarter by quarter, and its own filings carry a going-concern disclosure beyond the first quarter of 2027.

Recurrent respiratory papillomatosis is caused by HPV types 6 and 11 and is managed today by repeated surgery to keep the airway open. INO-3107 is a DNA immunotherapy designed to reduce that surgical burden. The FDA has granted it Orphan Drug and Breakthrough Therapy designations. The registrational evidence comes from the open-label RRP-001 trial in 32 patients, whose primary endpoint was safety and tolerability: 81.3%, or 26 of 32 patients, needed fewer surgical interventions in the year after dosing, and 28.1%, or nine of 32, needed none at all.

What matters now: the accelerated approval question is the whole file. If the agency accepts that a 32-patient open-label reduction in surgical interventions supports accelerated approval in a disease with no approved therapy, INOVIO gets its first product and a launch it has to fund. If it does not, the company is left with the same cash position and one fewer argument.

Merlintrader view: $INO is the highest-variance entry in this edition, and the ranking places it last deliberately. A dated FDA decision earns the slot; a single-arm 32-patient package, an unresolved eligibility question and a going-concern disclosure are the reasons it sits below every other dated decision on the list.